Biorepository for INvestigation of Diseases of the Lung (BRINDL) - Phase II

肺部疾病研究生物样本库 (BRINDL) - II 期

• 批准号: 10225235
• 负责人: GLORIA S PRYHUBER
• 金额: $ 135.78万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-23 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10225235
• 关键词: 3-Dimensional; Adopted; Adult; Age; Age-Years; Alveolar; Anatomy; Atlases; Awareness; Bioinformatics; Biological Assay; Biopsy; Cataloging; Catalogs; Cause of Death; Cell Nucleus; Cells; Cellular Structures; Child; Childhood; Chronic; Collaborations; Communities; Contracts; Country; Data; Databases; Deposition; Development; Diagnostic; Digital Imaging and Communications in Medicine; Disease; Elements; Ensure; Equipment and supply inventories; Erythema Infectiosum; Ethics; Family; Generations; Goals; High Resolution Computed Tomography; Histopathology; Human; Image; Imaging Techniques; Informatics; Information Systems; Infrastructure; Institutes; International; Investigation; Ischemia; Legal; Lung; Lung diseases; Medical center; Medicine; Metadata; Methods; Molecular; Molecular Profiling; Morbidity - disease rate; Morphologic artifacts; Neonatal; Nonprofit Organizations; Online Systems; Organ; Organ Donor; Pathologist; Phase; Physicians; Population; Pregnancy; Prevention; Procedures; Process; Program Development; Rare Diseases; Recording of previous events; Recovery; Research; Research Institute; Research Personnel; Resources; Respiratory physiology; Retrieval; Sampling; Source; Specific qualifier value; Specimen; Standardization; Structure; Structure of parenchyma of lung; System; Techniques; Time; Tissue imaging; Tissues; United Network for Organ Sharing; Universities; Work; biobank; cell type; developmental disease; disability-adjusted life years; effective therapy; emerging adult; human disease; human tissue; image archival system; lung development; microCT; mortality; multiple omics; novel; organ procurement transplantation network; preservation; programs; reconstruction; response; success; tissue processing; ultra high resolution; years of life lost

Lung disease originating in the period between the late canalicular stage to mature alveolarization and peak lung function, between limits of viability and early adulthood, remains a major cause of morbidity and mortality. Research to discover novel treatments for these disorders is limited by the rarity of access to normal and diseased human lung across this age span. Having, as the original Human Tissue Core (HTC) for the Molecular Atlas of Lung Development Program (LungMAP), created the BioRepository for INvestigation of Diseases of the Lung (BRINDL), the University of Rochester Medical Center (URMC) submits this application in response to RFA-HL-19-021 to continue to serve as the HTC for LungMAP Phase 2 (LungMAP II). BRINDL now contains over 200 human full lung sets, 50 normal by history and histopathology, spanning mid-late gestation to adult age, as well as an additional 70+ with specified disease. It will continue to be URMC-HTC responsibility to sufficiently identify and manage tissue sources to meet the overall Program goal to build an open-access, comprehensive, molecular atlas of the late- stage developing and maturing lung. As the HTC, URMC will collect, process, deposit, and distribute to the four LungMAP Research Centers (RCs), and ultimately the greater research community, human lung samples representing late gestation through early adulthood in forms that will support temporal and spatial characterization of molecular profiles of functionally or anatomically defined cell types in the developing lung. Per the RFA, the URMC-HTC will support the expansion of LungMAP to up to 25 years of age and to include neonatal and pediatric rare lung disease as well as normal lung development. Because of the concern and complexity in recovering high-quality pediatric lungs in a standardized manner and with as little ischemia-induced artifact as possible, and the need to meet all legal and ethical standards, we continue to choose to work primarily through elements of the United Network of Organ Sharing, the federally contracted Organ Procurement and Transplantation Network (OPTN), and two non-profit organizations to whom are referred non-transplantable donated organs suitable for research, The National Disease Research Interchange (NDRI) and the International Institute for the Advancement of Medicine (IIAM). NDRI and IIAM work well with the OPTN and with families who approach them directly during a pregnancy or illness expected to be lethal. In addition, we have contacts with Pediatric Pulmonary Centers around the country to identify potential sources for rare lung disease samples. Our goal is to provide an additional 250 lung set donations, or at minimum biopsies, for inclusion in the LungMAP BRINDL biorepository. Our URMC-HTC, in collaboration with Seattle Children’s Research Institute, will prepare the donated organs and tissues to meet the needs of the LungMAP Phase II RCs.

起源于小管晚期至成熟肺泡化期间的肺部疾病 在生存极限和成年早期之间的肺功能峰值仍然是发病的主要原因 发现这些疾病的新疗法的研究因获取途径的稀缺性而受到限制。 跨越这个年龄段的正常和患病的人类肺部，作为原始的人体组织核心。 (HTC) 为肺发育计划 (LungMAP) 分子图谱创建了 BioRepository 肺部疾病调查 (BRINDL)、罗切斯特大学医学中心 (URMC) 提交此申请以回应 RFA-HL-19-021，以继续担任 LungMAP 的 HTC 第 2 阶段（LungMAP II）现在包含 200 多个人类完整肺组，其中 50 个是正常的。 组织病理学，涵盖妊娠中晚期到成年，以及另外 70+ 特定的 充分识别和管理组织来源仍将是 URMC-HTC 的责任。 实现总体计划目标，即建立一个开放获取的、全面的最新分子图谱 作为 HTC，URMC 将收集、处理、存放并分发到处于发育和成熟阶段的肺。 四个 LungMAP 研究中心 (RC)，以及最终更大的研究社区——人类肺 代表妊娠晚期到成年早期的样本，其形式将支持时间和空间 发育中功能或解剖学定义的细胞类型的分子谱特征 根据 RFA，URMC-HTC 将支持将 LungMAP 扩展到 25 岁以下 包括新生儿和儿童罕见的肺部疾病以及正常的肺部发育。 以标准化方式和尽可能恢复高质量儿科肺部的关注点和复杂性 尽可能少地引起缺血引起的伪影，并且需要满足所有法律和道德标准，我们 继续选择主要通过器官共享联合网络、 联邦政府签约的器官采购和移植网络 (OPTN) 以及两个非营利组织 向其转介适合研究的不可移植捐赠器官的组织、国家 疾病研究交流中心 (NDRI) 和国际医学促进研究所 (NDRI) 和 IIAM 与 OPTN 以及在治疗期间直接联系他们的家庭合作良好。 此外，我们还与儿科肺科中心有联系。 我们的目标是在全国各地寻找罕见肺部疾病样本的潜在来源。 额外 250 个肺组捐赠或至少活检，以包含在 LungMAP BRINDL 中 我们的 URMC-HTC 将与西雅图儿童研究所合作准备 捐赠器官和组织以满足 LungMAP II 期 RC 的需求。